Cargando…
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and morbidity. However, approximately 10% of patients fails to respond adequately to current therapies and are considered treatment refractory,...
Autores principales: | Mantegazza, Renato, Antozzi, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791553/ https://www.ncbi.nlm.nih.gov/pubmed/29403543 http://dx.doi.org/10.1177/1756285617749134 |
Ejemplares similares
-
Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011) -
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023) -
From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020) -
Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020) -
Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)